Diabetes drug shows promise against advanced prostate cancer in new trial
NCT ID NCT07310433
First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 14 times
Summary
This study tests whether adding dapagliflozin, a common diabetes medication, to standard hormone therapy can help control metastatic prostate cancer better than hormone therapy alone. About 60 adults with advanced prostate cancer that has spread and is no longer responding to initial hormone treatment will take part. The goal is to see if the combination slows cancer growth and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.